Day: April 13, 2022

With 36.1% CAGR, Digital Signature Market Size worth USD 35.03 Billion in 2029

Written by Customer Service on April 13, 2022. Posted in Mergers And Acquisitions.

Major companies in the global digital signature market include Adobe, Onespan, Gemalto, Ascertia, Docusign, Entrust Datacard, Signix Inc., Identrust, Kofax, Globalsign, Zoho Corp, Rpost Technologies, Multicert, Hellosign. Pune, India, April 13, 2022 (GLOBE NEWSWIRE) — The global digital signature market size is projected to grow from USD 4.05 billion in 2022 to USD 35.03 billion by 2029, exhibiting a CAGR of 36.1% during the forecast period. The global market size was USD 3.00 billion in 2021. This information is published by Fortune Business Insights™, in its report, titled, “Digital Signature Market Share, 2022-2029.” The rising demand for e-businesses and paperless workflow is anticipated to drive the market. It is aiding industries such as retail, BFSI, healthcare, government, IT & telecom, among others, to decrease...

WarpSpeed Taxi Inc (WRPT) Schedules 3rd Round of Beta Testing

Written by Customer Service on April 13, 2022. Posted in Public Companies.

LAS VEGAS, NV, April 13, 2022 (GLOBE NEWSWIRE) — WarpSpeed Taxi Inc. (OTC Pink: WRPT) (“WarpSpeed” or the “Company”), the developer of an all-in-one software solution for ride hailing, food delivery, and courier services, is pleased to announce that it is commencing the 3rd round of beta testing of its WarpSpeed Taxi computer application. As previously announced, our initial beta launch is already underway in Ahmedabad, India, under the local brand of “Tezi Taxi”, which means “Fast Taxi” in Indian. As we move past beta testing, we will immediately launch our application across the rest of India, seeking to serve its large population of more than 1.3 billion people. The Indian operation will then be entrust with our operational team, which will launch the service in an additional country, with developers and designers on hand to...

Questor Announces December 31, 2021 Results

Written by Customer Service on April 13, 2022. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, April 13, 2022 (GLOBE NEWSWIRE) — Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announced today its financial and operating results for the fourth quarter and year ended December 31, 2021. Questor’s Consolidated Audited Financial Statements and Management’s Discussion and Analysis for the year ended December 31, 2021 are available on the Company’s website at www.questortech.com and through SEDAR at www.sedar.com. Unless otherwise noted, all financial figures are presented in Canadian dollars, prepared in accordance with International Financial Reporting Standards and are unaudited for the three months ended December 31, 2021. 2021 FINANCIAL RESULTS Three months ended December 31, Twelve months ended December 31, For the 2021 2020 2021 2020 Revenue 1,126,850 2,623,673 5,503,595 9,210,718 Gross...

Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update

Written by Customer Service on April 13, 2022. Posted in Earnings Releases And Operating Results.

– Q1 2022 consolidated sales grew 20%, supported by 35% growth in EGRIFTA SV®sales – TH1902 Phase 1/Part A enrollment at 300 mg/m2 dose nearing completion, potentially enabling recruitment of larger Phase 1/Part B expansion (basket trial) in the near term– Three poster presentations at AACR including new in vivo TH1902 Preclinical Data on its effect on Cancer Stem-like Cells (CD-133+)– Onboarding of commercial field force ongoing and to be fully completed by the end of April, 2022MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter of fiscal year 2022 ended...

GFG Finalizes WWCC Property Acquisition East of the Prolific Timmins Gold District

Written by Customer Service on April 13, 2022. Posted in Mergers And Acquisitions.

Figure 1: Regional Map of GFG Gold Projects in the Timmins Gold District Regional Map of GFG Gold Projects in the Timmins Gold DistrictFigure 2: Timmins East Regional Map of the Goldarm Property GFG Resources – Timmins East Regional Map of the Goldarm PropertySASKATOON, Saskatchewan, April 13, 2022 (GLOBE NEWSWIRE) — GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announces that the Company has completed its initial obligations pursuant to its previously announced definitive agreement (the “Agreement”) with International Explorers and Prospectors Inc. (“IEP”) to acquire a 100% interest in the 6,500-hectare WWCC property, subject to certain pre-existing encumbrances (the “Encumbrances”) (See news release dated February 24, 2022). In addition, the Company has staked a contiguous 6,800-hectare land...

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Written by Customer Service on April 13, 2022. Posted in Public Companies.

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients Acromegaly patients were exposed to Mycapssa® during the OPTIMAL Phase 3 Trial, including its open label extension (OLE), for a maximum treatment duration of 3.2 years Study demonstrated that 100% of evaluable patients who entered the 2nd year OLE phase of the study as responders – insulin–like growth factor 1 (IGF-1) within normal limits – maintained their long-term biochemical response at the end of the study IGF-1 levels were stably maintained within normal limits at the end of the OLE period (mean IGF-1 levels at baseline and at the end of the OLE were 0.92 and 0.84 respectively) Growth hormone (GH) levels also improved at the end of the OLE period...

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Written by Customer Service on April 13, 2022. Posted in Public Companies.

Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3 Illuminate results and post-hoc analyses to be presented at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting Corporate strategy to focus on accelerating the development of Axiomer® RNA base-editing technology platform across multiple therapeutic areas; Company to continue development of select Inherited Retinal Disease (IRD) programs, subject to regulatory feedback Company will implement restructuring initiatives including a 30% workforce reduction, extending cash runway into 2025 Conference call today at 8:00am...

HOOKIPA to Participate in the Kempen Life Sciences Conference

Written by Customer Service on April 13, 2022. Posted in Public Companies.

NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 – 21, 2022. About HOOKIPA HOOKIPA is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes...

Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022

Written by Customer Service on April 13, 2022. Posted in Public Companies.

ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company’s website at www.axogeninc.com and clicking on the webcast link. Following the conference...

SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2022 on May 10, 2022

Written by Customer Service on April 13, 2022. Posted in Public Companies.

BOSTON and LAUSANNE, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal 2022 before U.S. markets open on Tuesday, May 10, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator...

Day: April 13, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice